Structure Therapeutics Inc. GPCR
Structure Therapeutics Inc. (Nasdaq: GPCR) is a cardio-renal-metabolic drug developer. Its lead program, aleniglipron (GSBR-1290), is in Phase 3 for Chronic weight management (obesity/overweight with and without T2DM). Its next catalyst on record is aleniglipron: Body composition trial topline (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: aleniglipron — Body composition trial topline (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| aleniglipron - ACCOMPLISH-1 and ACCOMPLISH-2 Phase 3 | Obesity; obesity with T2DM | small molecule | Phase 3 |
| ACCG-2671 (oral amylin receptor agonist) | Obesity | small molecule | Phase 1 |
| LTSE-2578 (LPA1R antagonist) | Idiopathic pulmonary fibrosis | small molecule | Phase 1 |
| ACCG-3535 | Obesity | small molecule | Pre-clinical |
| GIP/GCG programs | Obesity | small molecule | Pre-clinical |
Recent results and decisions
- Sep 8, 2026positive SAD: ~6-day half-life, no SAEs, up to 3.3% mean body weight reduction after a single dose.
ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial
Filing - Aug 6, 2026started First patients dosed in Phase 3 ACCOMPLISH-1 (up to 3,600 patients).
The Company announced that the first patients have been dosed in the Phase 3 ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist.
Filing - May 7, 2026n/a Company received positive FDA end-of-Phase 2 feedback with clear guidance on the Phase 3 program (2.5 mg starting dose).
The Company received positive end-of-Phase 2 feedback from the U.S. Food and Drug Administration (FDA) and clear guidance on the Phase 3 program with a starting titration dose of 2.5 mg
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.